Prime Medicine Inc. (PRME)
NASDAQ · Healthcare
Prime Medicine Inc. EBITDA 2020–2025
Prime Medicine Inc. annual/quarterly ebitda history and growth rate from 2020 to 2025. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Prime Medicine Inc. ebitda for the quarter ending September 30, 2025 was -52.1 M, a 1.10% decrease year-over-year.
- Prime Medicine Inc. ebitda for the twelve months ending September 30, 2025 was -207.0 M, a 5.86% increase year-over-year.
- Prime Medicine Inc. annual ebitda for 2025 was -201.0 M, a 2.39% increase from 2024.
- Prime Medicine Inc. annual ebitda for 2024 was -196.3 M, a 1.90% decrease from 2023.
- Prime Medicine Inc. annual ebitda for 2023 was -200.1 M, a 75.07% increase from 2022.
- Prime Medicine Inc. annual ebitda for 2022 was -114.3 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Prime Medicine Inc. EBITDA — FAQ
Prime Medicine Inc. (PRME) ebitda over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see PRME's ebitda history?
The chart and table above show Prime Medicine Inc.'s ebitda by year and by quarter, including the growth rate.